Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 8/20 | 0.43 |
| ▸ | CTSS | P25774 | 4/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13864146 | 1.00 | CA1 (0.45) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL12336373 | 0.90 | CA1 (0.47) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL6169919 | 0.90 | CA1 (0.47) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL4458434 | 0.90 | CA1 (0.47) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL12119817 | 0.90 | CA1 (0.47) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL1552535 | 0.90 | CA1 (0.47) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL13520371 | 0.90 | CA1 (0.47) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL6474347 | 0.90 | CA1 (0.47) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL20745544 | 0.90 | CA1 (0.47) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL29323075 | 0.87 | CA1 (0.45) | CA1CA2CA7CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528264-B2 | Hydride reduction process for preparing quinolone intermediates | THE PROCTER & GAMBLE COMPANY (US) | 2009-05-05 | — | — | US | disclosed |
| US-20070232806-A1 | Hydride reduction process for preparing quinolone intermediates | THE PROCTER & GAMBLE COMPANY (US) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232806-A1 | Hydride reduction process for preparing quinolone intermediates | NQO1, NQO2, POR | CA1 3808/4885CA2 3365/4885CA7 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.